BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30577793)

  • 1. Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer.
    Ren J; Wang B; Li J
    BMC Syst Biol; 2018 Dec; 12(Suppl 8):130. PubMed ID: 30577793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer subtyping from plasma proteins.
    Zhang F; Chen JY
    BMC Med Genomics; 2013; 6 Suppl 1(Suppl 1):S6. PubMed ID: 23369492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
    Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
    J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
    Chang Y; Park KH; Lee JE; Han KC
    Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Label-free proteomic analysis of breast cancer molecular subtypes.
    Panis C; Pizzatti L; Herrera AC; Corrêa S; Binato R; Abdelhay E
    J Proteome Res; 2014 Nov; 13(11):4752-72. PubMed ID: 25221861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.
    Raj-Kumar PK; Lin X; Liu T; Sturtz LA; Gritsenko MA; Petyuk VA; Sagendorf TJ; Deyarmin B; Liu J; Praveen-Kumar A; Wang G; McDermott JE; Shukla AK; Moore RJ; Monroe ME; Webb-Robertson BM; Hooke JA; Fantacone-Campbell L; Mostoller B; Kvecher L; Kane J; Melley J; Somiari S; Soon-Shiong P; Smith RD; Mural RJ; Rodland KD; Shriver CD; Kovatich AJ; Hu H
    Breast Cancer Res; 2024 May; 26(1):76. PubMed ID: 38745208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
    Gökmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve SS
    PLoS One; 2018; 13(10):e0204658. PubMed ID: 30278072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein biomarkers for subtyping breast cancer and implications for future research.
    Mueller C; Haymond A; Davis JB; Williams A; Espina V
    Expert Rev Proteomics; 2018 Feb; 15(2):131-152. PubMed ID: 29271260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteogenomics connects somatic mutations to signalling in breast cancer.
    Mertins P; Mani DR; Ruggles KV; Gillette MA; Clauser KR; Wang P; Wang X; Qiao JW; Cao S; Petralia F; Kawaler E; Mundt F; Krug K; Tu Z; Lei JT; Gatza ML; Wilkerson M; Perou CM; Yellapantula V; Huang KL; Lin C; McLellan MD; Yan P; Davies SR; Townsend RR; Skates SJ; Wang J; Zhang B; Kinsinger CR; Mesri M; Rodriguez H; Ding L; Paulovich AG; Fenyö D; Ellis MJ; Carr SA;
    Nature; 2016 Jun; 534(7605):55-62. PubMed ID: 27251275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative proteomic and phosphoproteomic profiling of invasive micropapillary breast carcinoma.
    Chen X; Lin Y; Jin X; Zhang W; Guo W; Chen L; Chen M; Li Y; Fu F; Wang C
    J Proteomics; 2022 Apr; 257():104511. PubMed ID: 35139397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival.
    Tang W; Zhou M; Dorsey TH; Prieto DA; Wang XW; Ruppin E; Veenstra TD; Ambs S
    Genome Med; 2018 Dec; 10(1):94. PubMed ID: 30501643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated proteomic and phosphoproteomic analysis for characterization of colorectal cancer.
    Zhu H; Li Y; Guo J; Feng S; Ge H; Gu C; Wang M; Nie R; Li N; Wang Y; Wang H; Zhong J; Qian X; He G
    J Proteomics; 2023 Mar; 274():104808. PubMed ID: 36596410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.
    Buffard M; Naldi A; Freiss G; Deckert M; Radulescu O; Coopman PJ; Larive RM
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33670716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topological integration of RPPA proteomic data with multi-omics data for survival prediction in breast cancer via pathway activity inference.
    Kim TR; Jeong HH; Sohn KA
    BMC Med Genomics; 2019 Jul; 12(Suppl 5):94. PubMed ID: 31296204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstructing phosphorylation signalling networks from quantitative phosphoproteomic data.
    Invergo BM; Beltrao P
    Essays Biochem; 2018 Oct; 62(4):525-534. PubMed ID: 30072490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative phosphoproteomic analysis of a human tumor metastasis model using a label-free quantitative approach.
    Xie X; Feng S; Vuong H; Liu Y; Goodison S; Lubman DM
    Electrophoresis; 2010 Jun; 31(11):1842-52. PubMed ID: 20446291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoproteomic analysis of Her2/neu signaling and inhibition.
    Bose R; Molina H; Patterson AS; Bitok JK; Periaswamy B; Bader JS; Pandey A; Cole PA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9773-8. PubMed ID: 16785428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Proteomic and Phosphoproteomic Responses to Signaling Network Perturbations Reveals Functional Pathway Organizations in Yeast.
    Li J; Paulo JA; Nusinow DP; Huttlin EL; Gygi SP
    Cell Rep; 2019 Nov; 29(7):2092-2104.e4. PubMed ID: 31722220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.